Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse <6 months from end o...

Full description

Saved in:
Bibliographic Details
Published in:Am J Hematol
Main Authors: Costa, Luciano J., Maddocks, Kami, Epperla, Narendranath, Reddy, Nishitha M., Karmali, Reem, Umyarova, Elvira, Bachanova, Veronika, Costa, Cristiana, Glenn, Martha J., Chavez, Julio C., Calzada, Oscar, Lansigan, Frederick, Nasheed, Hossain, Barta, Stefan K., Zhou, Zheng, Jaglal, Michael, Chhabra, Saurabh, Hernandez-Ilizaliturri, Francisco, Xavier, Ana C., Mehta, Amitkumar, Peker, Deniz, Forero-Torres, Andreas, Al-Mansour, Zeina, Evens, Andrew M., Cohen, Jonathon B., Flowers, Christopher R., Fenske, Timothy S., Hamadani, Mehdi
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549936/
https://ncbi.nlm.nih.gov/pubmed/27880984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24615
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items